Alvotech Kicks Off Trials For Eylea Biosimilar

AVT06 Proposed Version Of Aflibercept Enters Clinical Studies

 
• By Dave Wallace

Alvotech has announced the start of clinical trials for its AVT06 proposed aflibercept biosimilar rival to Eylea, joining a host of other developers pursuing the same target.

Eye data binary
Trials are beginning for Alvotech’s aflibercept biosimilar • Source: Shutterstock

Alvotech has announced the start of trials for its AVT06 proposed biosimilar rival to Regeneron’s Eylea (aflibercept).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products